Antibody Information

General Information of This Antibody

Antibody ID	ANI0MDDEU
Antibody Name	Vadastuximab
Organization	Seagen Inc.
Indication	Acute myeloid leukemia; Acute promyelocytic leukemia; Myelodysplastic syndromes
Synonyms	h2H12ec Click to Show/Hide
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Chimeric IgG1-kappa
Antigen Name	Myeloid cell surface antigen CD33 (CD33)	Antigen Info
ChEMBI ID	CHEMBL3990024
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence	XVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKY NEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSSAST KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLY SLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPCV FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTK NQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQG NVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
Heavy Chain Varible Domain	QVQLVQSGAEVKKPGASVKVSCKASGYTFTNYDINWVRQAPGQGLEWIGWIYPGDGSTKY NEKFKAKATLTADTSTSTAYMELRSLRSDDTAVYYCASGYEDAMDYWGQGTTVTVSS Click to Show/Hide
Heavy Chain Constant Domain 1	ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKV Click to Show/Hide
Heavy Chain Constant Domain 2	APELLGGPCVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK Click to Show/Hide
Heavy Chain Constant Domain 3	GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK Click to Show/Hide
Heavy Chain Hinge Region	EPKSCDKTHTCPPCP Click to Show/Hide
Heavy Chain CDR 1	GYTFTNYD Click to Show/Hide
Heavy Chain CDR 2	IYPGDGST Click to Show/Hide
Heavy Chain CDR 3	ASGYEDAMDY Click to Show/Hide
Light Chain Sequence	DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPS RFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIKRTVAAPSVFIFPP SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain Varible Domain	DIQMTQSPSSLSASVGDRVTINCKASQDINSYLSWFQQKPGKAPKTLIYRANRLVDGVPS RFSGSGSGQDYTLTISSLQPEDFATYYCLQYDEFPLTFGGGTKVEIK Click to Show/Hide
Light Chain Constant Domain	RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC Click to Show/Hide
Light Chain CDR 1	QDINSY Click to Show/Hide
Light Chain CDR 2	RAN Click to Show/Hide
Light Chain CDR 3	LQYDEFPLT Click to Show/Hide

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

Vadastuximab talirine [Phase 3 (discontinued)]

ADC Info

Identified from the Human Clinical Data

Click To Hide/Show 12 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Patients Enrolled	Eligibility required untreated MDS (WHO 2008) patients ≥18 years with ECOG ≤2 and adequate organ function, excluding prior lenalidomide/HMA treatment, active secondary malignancies (except hormonal therapies), or candidates for immediate stem cell transplant.
Administration Dosage	Intravenous (IV) push every 4 weeks
*Related Clinical Trial*
NCT Number	NCT02706899	Clinical Status	PHASE1\|\|\|PHASE2
Clinical Description	A Phase 1/2 Study of Vadastuximab Talirine (SGN-CD33A) in Combination With Azacitidine in Patients With Previously Untreated International Prognostic Scoring System (IPSS) Intermediate-2 or High Risk Myelodysplastic Syndrome (MDS)
Primary Endpoint	The phase 1 study evaluating vadastuximab talirine was terminated before establishing a recommended phase 2 dose, with only dose delays/reductions reported, while phase 2 efficacy endpoints (ORR, CR, HI, DOR, PFS, AML transformation, OS) were not assessed due to study discontinuation.
Other Endpoint	Safety analysis captured adverse events and lab abnormalities over 1 year, though all planned phase 2 efficacy comparisons per IWG 2006 criteria (including CR rate, hematologic improvement, and survival outcomes) remained unevaluated following early trial termination.
Experiment 2 Reporting the Activity Date of This ADC				[2]
Patients Enrolled	Eligible patients had untreated intermediate/adverse-risk AML (WHO-classified, excluding APL/favorable karyotypes) suitable for HMA therapy, while excluding prior MDS treatment recipients, transplant candidates, and those with myeloproliferative neoplasm histories.
Administration Dosage	33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
*Related Clinical Trial*
NCT Number	NCT02785900	Clinical Status	PHASE3
Clinical Description	A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Primary Endpoint	The study evaluated overall survival (1.5 years) and composite complete remission (CRc) rate per Cheson 2003 criteria, while assessing MRD-negative CRc status and time to CR/CRi within the same timeframe.
Other Endpoint	Secondary endpoints included duration of remission (9.5 months), event-free survival (11.24 months), leukemia-free survival (9.49 months), safety profile (TEAEs, grade ≥3 lab abnormalities over 1.5 years), and 30-/60-day mortality rates, with censoring rules applied for patients receiving subsequent therapies.
Experiment 3 Reporting the Activity Date of This ADC				[3]
Patients Enrolled	Eligible participants had CD33+ AML with ECOG 0-1, adequate organ function, and either relapsed after ≥12-week remission or were untreated with ≥20% blasts, excluding recent transplant recipients (except designated cohort) or those receiving recent antileukemic therapy.
Administration Dosage	Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
*Related Clinical Trial*
NCT Number	NCT01902329	Clinical Status	PHASE1
Clinical Description	A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia
Primary Endpoint	The study monitored adverse events and laboratory abnormalities through 1 month post-treatment, while evaluating pharmacokinetics (SGN-CD33A blood concentrations for 3 weeks) and immunogenicity (antitherapeutic antibody incidence).
Other Endpoint	Efficacy assessments included complete remission rate (3 months), duration of response (3 years), relapse-free survival (3 years), and overall survival (3 years) in CD33-positive AML patients.
Experiment 4 Reporting the Activity Date of This ADC				[4]
Patients Enrolled	The trial enrolled AML patients (excluding APL) with ECOG 0-1 and adequate organ function, stratifying by treatment phase (induction/consolidation/maintenance), while excluding those with prior MDS/MPN therapy or cardiopulmonary dysfunction in dose-escalation cohorts.
Administration Dosage	7+3 (Standard dose cytarabine for induction and daunorubicin) + SGN-CD33A Drug: SGN-CD33A, Given intravenously Day 1 or Days 1 and 4 of each cycle
*Related Clinical Trial*
NCT Number	NCT02326584	Clinical Status	PHASE1
Clinical Description	A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Primary Endpoint	Safety assessments included adverse events, laboratory abnormalities, and dose-limiting toxicities monitored through 1 month post-treatment, establishing the preliminary safety profile of SGN-CD33A in AML patients.
Other Endpoint	Efficacy outcomes measured CR rate post-induction, leukemia-free survival, and overall survival (up to 3 years), while pharmacokinetic parameters (drug concentrations, ATA incidence) and MRD clearance rates were tracked longitudinally throughout the study duration.
Experiment 5 Reporting the Activity Date of This ADC				[5]
Patients Enrolled	Inclusion criteria: Adults ≥18 with isolated distal femur fractures requiring LISS plating, compliant with 1-year MGH follow-ups. Exclusion: Life expectancy <1 year, pre-injury non-ambulatory status, pregnancy, non-LISS implants, bone disorders, neoplasm-related fractures, severe open fractures with vascular damage, or inability to attend follow-ups. Click to Show/Hide
*Related Clinical Trial*
NCT Number	NCT01593176	Clinical Status	N.A.
Clinical Description	Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures
Primary Endpoint	The study evaluates inter-fragmentary motion changes in distal femoral fractures using radiostereometric analysis at postoperative intervals (2 weeks, 6 weeks, 3/6/12 months) to assess healing dynamics.
Experiment 6 Reporting the Activity Date of This ADC				[6]
Efficacy Data	Incomplete Count Recovery (CRi)	26%
Patients Enrolled	Older patients with newly diagnosed acute myeloid leukemia (AML).
Administration Dosage	33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m², SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m², iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m², SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m², iv x 5 days, every 4 weeks.
*Related Clinical Trial*
NCT Number	NCT02326584	Clinical Status	Phase 1
Clinical Description	A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia.
Experiment 7 Reporting the Activity Date of This ADC				[7]
Efficacy Data	Complete Remission (CR)	66.70%
Patients Enrolled	Patients With Relapsed or Refractory AmL.
Administration Dosage	Post-allo after stem cell transplant in Day 1 of each cycle; Pre-allo in Day 1 of each cycle plus melphalan 30 mg/m²/day iv and fludarabine 140 mg/m² iv before stem cell transplant.
*Related Clinical Trial*
NCT Number	NCT02785900	Clinical Status	Phase 3
Clinical Description	A randomized, double-blind phase 3 study of vadastuximab talirine (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukemia (AML).
Experiment 8 Reporting the Activity Date of This ADC				[8]
Efficacy Data	Complete Remission (CR)	11.00 12.00 22.00 23.00 %
Patients Enrolled	CD33-positive AmL (any level of CD33 expression as detected by local flow cytometric assessment) and had either newly diagnosed AmL (declining intensive induction/consolidation chemotherapy) or AmL relapsed after a minimum remission duration of 12 weeks after intensive induction/consolidation.
Administration Dosage	Slow IV push on day 1 (5-60 ug/kg) or on days 1 and 4 (20 ug/kg) of 21-day cycles.
*Related Clinical Trial*
NCT Number	NCT01902329	Clinical Status	Phase 1
Clinical Description	A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.
Primary Endpoint	The recommended monotherapy dose is 4.00 mg/kg.
Other Endpoint	The complete remission rate (CRc) among the 69 patients in the dose-finding cohorts, was 19.00% (6.00% CR + 13.00% CRi, 95% confidence interval [CI], 10.40-30.10).
Experiment 9 Reporting the Activity Date of This ADC				[6]
Efficacy Data	Complete Remission (CR)	30.00 26.00 %
Patients Enrolled	Older patients with newly diagnosed acute myeloid leukemia (AML).
Administration Dosage	33A, iv, 10 mcg/kg, every 4 weeks plus azacitidine 75 mg/m², SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m², iv x 5 days, every 4 weeks; placebo plus plus azacitidine 75 mg/m², SC or IV x 7 days, every 4 weeks or decitabine 20 mg/m², iv x 5 days, every 4 weeks.
*Related Clinical Trial*
NCT Number	NCT02326584	Clinical Status	Phase 1
Clinical Description	A phase 1b dose-escalation study of SGN-CD33A in combination with standard-of-care for patients with newly diagnosed acute myeloid leukemia.
Experiment 10 Reporting the Activity Date of This ADC				[9]
Efficacy Data	Complete Remission (CR)	43.00 42.00 34.00 80.00 50.00 39.00 %
Patients Enrolled	New diagnosis of CD33-expressing AmL, they could not have received prior therapy with HMAs; however, prior low-intensity treatment, such as hydroxyurea for cytoreduction or other low-intensity therapies for preceding myelodysplastic syndrome (MDS), an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1, with adequate baseline renal, hepatic, and pulmonary function. Click to Show/Hide
Administration Dosage	Azacitidine (75 mg/m² subcutaneous/intravenous 7 days) or decitabine (20 mg/m² intravenous 5 days) was administered per institutional standard. On the final day of HMA administration (day 7 of azacitidine treatment and day 5 of decitabine treatment), vadastuximab talirine (10 ug/kg) was administered via slow intravenous push (1-2 mL/min), after infusion of the HMA, as 28-day cycles for up to 4 cycles of treatment. Click to Show/Hide
*Related Clinical Trial*
NCT Number	NCT01902329	Clinical Status	Phase 1
Clinical Description	A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.
Primary Endpoint	The 30- and 60-day mortality rates were 2% and 8%, respectively. No DLTs or infusion-related reactions were observed in the combination cohort of this study.
Other Endpoint	CR and CRi, was 70.00% (43% CR + 26% CRi, 95% CI, 55.70-81.70). Median RFS was 7.70 months (95% CI, 4.90-15.40) with 11.30 months (95% CI, 8.80-13.20) median OS.
Experiment 11 Reporting the Activity Date of This ADC				[10]
Patients Enrolled	Patients with operable HER2-positive primary breast cancer.
Administration Dosage	Anthracycline then Trastuzumab Emtansine and Pertuzumab ; Anthracycline then Trastuzumab, Pertuzumab, and Taxane.
*Related Clinical Trial*
NCT Number	NCT02614560	Clinical Status	Phase 1/2
Clinical Description	A phase 1/2 study of vadastuximab talirine administered in sequence with allogeneic hematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukemia (AML).
Experiment 12 Reporting the Activity Date of This ADC				[11]
Patients Enrolled	Patients With acute myeloid leukemia (AML).
Administration Dosage	SGN-CD33A iv in Day 1 or Days 1 and 4 of each cycle; High dose cytarabine + SGN-CD33A (28-day cycles); Standard dose cytarabine and daunorubicin + SGN-CD33A; standard dose cytarabine and daunorubicin + SGN-CD33A and High dose cytarabine + SGN-CD33A.
*Related Clinical Trial*
NCT Number	NCT01902329	Clinical Status	Phase 1
Clinical Description	A phase 1 trial of SGN-CD33A in patients with CD33-positive acute myeloid leukemia.

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 8 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 0%	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells (Multidrug resistance)		CVCL_2481
Experiment 2 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 29.44%	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 30mcg/kg.
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 3 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 47.77%	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells (Multidrug resistance)		CVCL_2481
Experiment 4 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 78.95%	Negative CD33 expression (CD33-)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model	Anaplastic thyroid cancer	TF1-alpha cells (Multidrug resistance)		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.41%	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 1000mcg/kg.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells (Multidrug resistance)		CVCL_2481
Experiment 6 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 98.53%	Negative CD33 expression (CD33-)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model	Anaplastic thyroid cancer	TF1-alpha cells (Multidrug resistance)		Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.99%	Negative CD33 expression (CD33-)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 300mcg/kg.
In Vitro Model	Anaplastic thyroid cancer	TF1-alpha cells (Multidrug resistance)		Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 99.99%	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was compared with control ADC against various human cancer cell lines in vivo. The cells were treated with 100mcg/kg.
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002

Revealed Based on the Cell Line Data

Click To Hide/Show 33 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=3,919)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG019		Homo sapiens
Experiment 2 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.1 ng/mL	Moderate CD33 expression (CD33++; 6,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Childhood acute monocytic leukemia	MV4-11 cells		CVCL_0064
Experiment 3 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	High CD33 expression (CD33+++; CD33 MFI=11,850)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG015		Homo sapiens
Experiment 4 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	High CD33 expression (CD33+++; CD33 MFI=10,762)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG018		Homo sapiens
Experiment 5 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG023		Homo sapiens
Experiment 6 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=1,355)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG014		Homo sapiens
Experiment 7 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.2 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG022		Homo sapiens
Experiment 8 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.4 ng/mL	Low CD33 expression (CD33+; CD33 MFI=107)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG003		Homo sapiens
Experiment 9 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	0.9 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=5,817)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG002		Homo sapiens
Experiment 10 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	1 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Adult acute myeloid leukemia	HL-60 cells		CVCL_0002
Experiment 11 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	3 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Adult acute myeloid leukemia	KG-1 cells		CVCL_0374
Experiment 12 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	5 ng/mL	Negative CD33 expression (CD33-; CD33 MFI=20)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG017		Homo sapiens
Experiment 13 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	Negative CD33 expression (CD33-; CD33 MFI=49)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG001		Homo sapiens
Experiment 14 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	6 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Acute myeloid leukemia	SH-1 cells		CVCL_2191
Experiment 15 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Childhood acute monocytic leukemia	THP-1 cells		CVCL_0006
Experiment 16 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	7 ng/mL	High CD33 expression (CD33+++; CD33 MFI=23,223)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Erythroleukemia	HEL 92.1.7 cells		CVCL_2481
Experiment 17 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 7.5 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Acute myeloid leukemia	SIG-M5 cells		CVCL_1694
Experiment 18 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Low CD33 expression (CD33+; CD33 MFI=216)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG013		Homo sapiens
Experiment 19 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	11 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=1,035)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG008		Homo sapiens
Experiment 20 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	22 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Adult acute monocytic leukemia	U-937 cells		CVCL_0007
Experiment 21 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	23 ng/mL	Low CD33 expression (CD33+; CD33 MFI=299)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG010		Homo sapiens
Experiment 22 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	26 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Acute myeloid leukemia	HNT-34 cells		CVCL_2071
Experiment 23 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	32 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=1,184)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG004		Homo sapiens
Experiment 24 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	33 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=6,598)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG011		Homo sapiens
Experiment 25 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	49 ng/mL	Moderate CD33 expression (CD33++; CD33 MFI=2,278)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Anaplastic thyroid cancer	TF1-alpha cells (Multidrug resistance)		Homo sapiens
Experiment 26 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	61 ng/mL	Moderate CD33 expression (CD33++; 7,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Esophageal squamous cell carcinoma	TF-1 cells		CVCL_1759
Experiment 27 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	68 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Adult acute myeloid leukemia	SH-2 cells		CVCL_2190
Experiment 28 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 100 ng/mL	Negative CD33 expression (CD33-; CD33 MFI=0)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG009		Homo sapiens
Experiment 29 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 110 ng/mL	Low CD33 expression (CD33+; CD33 MFI=353)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG012		Homo sapiens
Experiment 30 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 110 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in primary AmL samples in vitro.
In Vitro Model	Acute myeloid leukemia	Acute myeloid leukemia cells #SG020		Homo sapiens
Experiment 31 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	Low CD33 expression (CD33+; CD33 MFI=318)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian clear cell adenocarcinoma	ES-2 cells		CVCL_3509
Experiment 32 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 1000 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Burkitt lymphoma	Ramos cells		CVCL_0597
Experiment 33 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	> 5000 ng/mL	High CD33 expression (CD33+++; 23,000 CD33 receptor copy number)
Method Description	The inhibitory activity of SGN-CD33A against cancer cell growth was evaluated in various human cancer cell lines in vitro.
In Vitro Model	Ovarian serous cystadenocarcinoma	SK-OV-3 cells		CVCL_0532

References

Ref 1	Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS
Ref 2	Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Ref 3	A Safety Study of SGN-CD33A in AML Patients
Ref 4	A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML
Ref 5	Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures
Ref 6	A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia, NCT02326584
Ref 7	A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), NCT02785900
Ref 8	A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Blood. 2018 Jan 25;131(4):387-396.
Ref 9	A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood. 2018 Sep 13;132(11):1125-1133.
Ref 10	A Phase 1/2 Study of Vadastuximab Talirine Administered in Sequence With Allogeneic Hematopoietic Stem Cell Transplant in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML), NCT02614560
Ref 11	A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia, NCT01902329
Ref 12	SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013 Aug 22;122(8):1455-63.

Antibody Information

Citation

Visitor Map

Correspondence

Prof. Feng ZHU (zhufeng@zju.edu.cn)

Prof. Xiaowu DONG (dongxw@zju.edu.cn)

Prof. Luo FANG (fangluo@zjcc.org.cn)